ASENAPINE MALEATE Drug Patent Profile

Which patents cover Asenapine Maleate, and what generic alternatives are available?

Asenapine Maleate is a drug marketed by Alembic, Breckenridge, and Sigmapharm Labs Llc. and is included in three NDAs.

The generic ingredient in ASENAPINE MALEATE is asenapine maleate. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the asenapine maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Asenapine Maleate

A generic version of ASENAPINE MALEATE was approved as asenapine maleate by ALEMBIC on December 10^th, 2020.

Summary for ASENAPINE MALEATE

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	64
Clinical Trials:	2
Patent Applications:	247
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ASENAPINE MALEATE
DailyMed Link:	ASENAPINE MALEATE at DailyMed

Recent Clinical Trials for ASENAPINE MALEATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Accutest Research Laboratories (I) Pvt. Ltd.	Phase 2/Phase 3
Amneal Pharmaceuticals, LLC	Phase 2/Phase 3
bioRASI, LLC	Phase 1

See all ASENAPINE MALEATE clinical trials

Pharmacology for ASENAPINE MALEATE

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for ASENAPINE MALEATE

N05AH	Diazepines, oxazepines, thiazepines and oxepines
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for ASENAPINE MALEATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SAPHRIS	Sublingual Tablets	asenapine maleate	2.5 mg	022117	1	2017-07-27
SAPHRIS	Sublingual Tablets	asenapine maleate	5 mg and 10 mg	022117	4	2013-08-13

US Patents and Regulatory Information for ASENAPINE MALEATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	206098-003	Jul 19, 2021	AB	RX	No	No
Sigmapharm Labs Llc	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	206107-001	Dec 10, 2020	AB	RX	No	No
Breckenridge	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	205960-001	Dec 10, 2020	AB	RX	No	No
Sigmapharm Labs Llc	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	206107-002	Dec 10, 2020	AB	RX	No	No
Alembic	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	206098-001	Dec 10, 2020	AB	RX	No	No
Alembic	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	206098-002	Dec 10, 2020	AB	RX	No	No
Breckenridge	ASENAPINE MALEATE	asenapine maleate	TABLET;SUBLINGUAL	205960-002	Dec 10, 2020	AB	RX	No	No

Market Dynamics and Financial Trajectory for Asenapine Maleate

Last updated: February 13, 2026

Overview:
Asenapine maleate is an atypical antipsychotic approved by the FDA in 2009 for adult schizophrenia and bipolar disorder. Its market presence remains modest, driven by competitive drugs and shifting prescribing trends. The drug’s financial trajectory is shaped by market penetration, patent status, off-label use, and emerging competitors.

Market Size and Growth Factors

• Global Market Value: The global antipsychotic drugs market was valued at approximately $9 billion in 2022, with expectations to reach $12 billion by 2027, at a CAGR of 5.8% (source: Markets and Markets[1]).
• Asenapine’s Share: Asenapine constitutes a small fraction: approximately 2-3%, given dominance by drugs like risperidone and aripiprazole.
• Regional Differences:
  • U.S. accounts for roughly 60% of the market, driven by high diagnosis rates and access to pharmaceuticals.
  • Europe and Asia-Pacific show slower adoption, with considerable variation in prescribing practices.

Market Dynamics

• Competitive Landscape:
  • The market is dominated by risperidone, quetiapine, and aripiprazole, which collectively account for over 70% of revenue.
  • Asenapine’s unique sublingual formulation offers advantages in compliance but faces stiff competition from oral and long-acting injectables.
• Pricing and Reimbursement:
  • Asenapine’s average wholesale price (AWP) is approximately $20–$25 per day, comparable to other atypical antipsychotics.
  • Reimbursement policies favor drugs with established long-term efficacy and safety, limiting market share expansion for newer entrants like asenapine.
• Regulatory and Patent Factors:
  • Patent expiration of the original formulation was in 2017.
  • The drug is now available as a generic, impacting pricing power and profit margins.

Financial Trajectory

• Revenue Trends:
  • Peak sales occurred around 2013–2015, estimated at $250–$300 million annually for the branded product.
  • Post-generic entry, sales have declined by approximately 20–30% annually, with current estimates around $50–$70 million worldwide.
• Profitability:
  • Margins are compressed due to generic competition.
  • R&D and marketing expenses decline proportionally with sales, limiting new revenue growth without reformulation or new indications.

Pipeline and Future Potential

• New Indications:
  • Trial data suggests potential for adjunctive use in treatment-resistant depression or as part of combination therapy, which could reopen revenue streams.
• Formulation Innovations:
  • Development of new delivery methods could improve adherence and clinical outcomes, increasing market viability.
• Market Entry Barriers:
  • Existing competitors with long-acting injectables and newer antipsychotics pose significant hurdles.
  • Patent and exclusivity periods are exhausted, reducing exclusivity advantages.

Key Financial and Strategic Considerations

Factor	Impact	Notes
Patent Status	Market entry of generics	Loss of patent in 2017 reduces exclusivity
Market Penetration	Limited	Small market share compared to dominant drugs
Competition	High	Long-acting formulations and newer agents dominate
Pricing Power	Low	Generic market pressures
Investment in New Uses	Low	Little evidence of significant pipeline developments

Conclusion:
Asenapine maleate's financial prospects have diminished since patent expiry. Revenue continues to decline, constrained by entrenched competition, generic pricing, and limited expansion pathways. Future growth hinges on new clinical indications, formulation advances, or regulatory approvals for novel uses.

---

Key Takeaways

• Asenapine maleate's global sales peaked around 2013–2015 and have since declined due to generic competition.
• The drug commands a small market share in the global antipsychotic segment.
• Current revenue is estimated at $50–$70 million, with margins pressured by generics.
• Future growth relies on new indications or formulations, with limited near-term potential.
• Competition from long-acting injectables and newer antipsychotics remains a significant barrier.

---

FAQs

1. How does asenapine maleate compare to other atypical antipsychotics in terms of efficacy?
Clinical trials show comparable efficacy, but prescribing habits favor drugs with established long-term safety profiles and convenient dosing.

2. What are the primary reasons for declining sales of asenapine?
Patent expiration led to generic entry, increased competition, and limited differentiation from other agents.

3. Is there potential for asenapine to regain market share?
Limited unless new indications, formulations, or delivery methods demonstrate significant benefits and regulatory approval.

4. How does pricing compare between branded and generic asenapine?
Branded formulations typically priced at $20–$25 per day; generic versions are priced significantly lower, reducing profitability for manufacturers.

5. What regulatory hurdles exist for future asenapine development?
Need for new clinical trials for additional indications, and challenges in demonstrating superiority over existing therapies.

---

Sources:
[1] Markets and Markets. "Antipsychotic Drugs Market," 2022.